Shionogi Agrees to Acquire IntraBio for $2 Billion

Company Shionogi; IntraBio Event Type Acquisition Modality Small molecule Asset AQNEURSA (levacetylleucine) Target Mechanism incompletely defined Disease Area Niemann-Pick disease type C; ataxia-telangiectasia Summary Shionogi agreed to acquire IntraBio for $2.0 billion upfront, adding the oral levacetylleucine franchise and a rare-neurology pipeline. Recent approvals establish…